15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Edwards Lifesciences Corp, 15 rate it Buy or better, 5 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $85.00 to $110.00, so the covering firms are broadly aligned. The average target of $101.94 sits 18% above the current $86.24. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 14 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.71 next quarter toward $3.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Moderate Buy
Strong Buy00%
Buy1575%
Hold525%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Edwards Lifesciences Corp.
As of Sep, 15 of 20 firms rate EW a Buy (5 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
EW EPS & revenue forecast
EPS · NEXT QUARTER
$0.71
Range $0.67 – $0.76 · 23 analysts · +22% YoY
Next period, 23 analysts expect Edwards Lifesciences Corp to earn $0.71 a share (range $0.67 – $0.76), versus $0.58 a year earlier. Full-year consensus is $3.00, growing to $3.38 the year after.
REVENUE · NEXT QUARTER
$1.7B
Range $1.7B – $1.7B · 23 analysts · +8% YoY
Revenue is expected to reach $1.7B (range $1.7B – $1.7B), +8.4% year-over-year. Full-year consensus is $6.8B, rising to $7.4B next year.
Top analysts covering Edwards Lifesciences Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EW.
#1
Anthony Petrone
Mizuho · Rank #86
Buy
$105.00+21.8% to target
Overall win rate
46%
+ Follow
#2
JB
Jayson Bedford
Raymond James · Rank #196
Buy
$96.00+11.3% to target
Overall win rate
42%
+ Follow
#3
William Plovanic
Canaccord Genuity · Rank #243
Hold
$85.00-1.4% to target
Overall win rate
37%
+ Follow
#4
Richard Newitter
Truist Securities
Hold
$95.00+10.2% to target
Coverage
—
+ Follow
#5
MT
Marie Thibault
BTIG
Buy
$110.00+27.6% to target
Coverage
—
+ Follow
EW stock forecast FAQ
What is EW's average 12-month price target?+
The 17 analysts with a live target average $101.94 for Edwards Lifesciences Corp over the next 12 months, ranging from a $110.00 high to a $85.00 low.
Is EW stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 20 analyst ratings, 15 are Buy or Strong Buy, 5 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for EW?+
The Street-high target is $110.00 (UBS), and the Street-low is $85.00 (Canaccord Genuity). The average of all 17 active targets is $101.94.
How many Wall Street analysts cover EW?+
20 analysts have an active rating on Edwards Lifesciences Corp, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering EW?+
Among analysts who currently cover EW, Anthony Petrone of Mizuho has the strongest overall Quantellect track record (Rank #86). Their current call is Buy with a $105.00 target.
What is Edwards Lifesciences Corp's projected EPS for next quarter?+
The consensus estimate is $0.71 per share (range $0.67 – $0.76) across 23 analysts. Full-year EPS is projected at $3.00, rising to $3.38 the following year.
How much revenue is Edwards Lifesciences Corp expected to report next quarter?+
Consensus revenue is $1.7B (range $1.7B – $1.7B). Full-year revenue is projected at $6.8B, growing to $7.4B next year.
Have analysts been upgrading or downgrading EW lately?+
As of Sep, 15 of 20 firms rate EW a Buy (5 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EW calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
UBS
